Ultragenyx Pharmaceutical Inc: Phase 3 study closed enrollment, 69 enrolled (Long-chain Fatty Acid Oxidation Disorders (LC-FAOD))
Ultragenyx Pharmaceutical Inc: Phase 3 study closed enrollment, 69 enrolled (Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)). Its enrollment of 69 is below the median of 80 (45th percentile). Dated 49 days ago, it serves as a historical benchmark. Score 65/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 69 · 45th percentile of 8,879 ClinicalTrialStartPulse records · 0.9x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Ultragenyx Pharmaceutical Inc |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD |
| NCT ID | NCT05933200 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) |
| Intervention types | drug, dietary supplement |
| Target enrollment | 69 |
| Site countries | Czechia, Germany, Japan, Poland, Saudi Arabia, Spain, Turkey (Türkiye) |
| Posted | 2023-07-06 |
| Planned start | 2023-02-28 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-09-17 |
| Last update posted | 2026-09-17 |
| enrollment percentile | 45th of 8,879 (median 80, 0.9x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Ultragenyx Pharmaceutical Inc
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Ultragenyx Pharmaceutical + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-09-17
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Ultragenyx Pharmaceutical Inc and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Ultragenyx Pharmaceutical Inc's enrollment: 45th percentile of 8,879 records
- Timing: Low: older than 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
65 / 100 Score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
What is the ClinicalTrialStartPulse record for Ultragenyx Pharmaceutical Inc?
Ultragenyx Pharmaceutical Inc's Phase 3 study (NCT05933200) in Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), first posted 2023-07-06: enrollment closed (active, not recruiting) (2026-09-17), in an update posted 2026-09-17.
How does Ultragenyx Pharmaceutical Inc compare to other ClinicalTrialStartPulse records?
Its enrollment of 69 is below the median (45th percentile); smaller records often move faster and face less competition. It is 49 days old; check the official source for later updates before acting.
Ultragenyx Pharmaceutical Inc vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc | NONUS | 69 | 45th | 2026-09-17 |
| Janssen-Cilag Ltd. | US | 120 | 65th | 2026-11-03 |
| NervGen Pharma | US | 150 | 71st | 2026-11-03 |
| Janssen Research & Development, LLC | US | 159 | 72nd | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: Outside the US only
How to monitor Ultragenyx Pharmaceutical Inc and peer phase 3 records
Get new ClinicalTrialStartPulse records like Ultragenyx Pharmaceutical Inc by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.